ENDO 2018: 100th Endocrine Society Annual Meeting :

Exclusive Video Highlights from Chicago

A brief overview of select poster abstracts and session highlights:

Estrogen Administration Improves Disordered Eating

Franziska Lessow, PhD, an instructor in medicine (psychology) at Harvard Medical School/Massachusetts General Hospital, and Vibna Singhal, MD, a pediatric endocrinologist and obesity medicine physician in the weight center at MassGeneral Hospital for Children, in Boston, Massachusetts, presented results of a cross-sectional study of 208 young female athlete, ages 14-25 years old, who were at normal weight but presented with oligo-amenorrhea. The authors reported that 12 months of physiological estrogen replacement therapy improved disordered eating behavior and psychopathology including body dissatisfaction and perfectionism.1

“There have been issues of resistance to even a low dose of estrogen from the girls and their parents; however, to improve treatment acceptance, we explain that the estrogen, delivered by transdermal patch, offers a more physiological introduction that is far better than the symptoms that brought them to the clinic in the first place,” Dr. Singhal told EndocrineWeb. This poster was acknowledged with an outstanding abstract award

Assessing a New Class of Androgens in Diagnosing PCOS

Andrea E. Dunaif, MD, chief of endocrinology at Ichan School of Medicine at Mount Sinai in New York City, presented findings from two abstracts looking at levels of a new class of androgens--C19 11 oxygenated androgens, one in prepubescent at-risk daughters of mothers with polycystic ovary syndrome (PCOS) and adult women.

Clinical Presentation on Bone Mets in Prostate Cancer
Alice Levine, MD, professor of medicine, and co-founder/co-director of the adrenal center at the Icahn School of Medicine at Mount Sinai in New York City, presented on advances in the treatment of bone metastases in prostate cancer. Her team is studying the role of an old marker, prostatic acid phosphatase (PAP), in building new bone in osteoblastic prostate cancer bone metastases.

“We have been looking at the activation of PAP, a secretory phosphatase, actually enhancing osteoblast differentiation and also mineralization; and, we are working on antibodies directed a PAP for the treatment of men with osteoblastic bone Mets due to prostate cancer,” Dr. Levine told EndocrineWeb, in summarizing her research findings in a session on the involvement of bone demineralization due to cancer.

Advancing Transgender Medical Care

Addressing health disparities in medical school curricula has not translated to knowledge of or favorable attitudes concerning the care of patients who identify as transgender. Only 4% of responding members of the Endocrine Society indicated on transgender healthcare during their medical training,1 demonstrating a need to enhance the medical school curriculum, for example, addressed students’ values such as believing that being transgender is a choice was one topic addressed to increase future physicians’ comfort in working with this patient population.2

Anna Jane Najor, a second-year medical student at Mayo Clinic School of Medicine in Rochester, Minnesota, introduced an effective evidenced-based approach to improving physician comfort in the delivery of care to transgender patients by integrating clinical content throughout a four-year medical school curriculum.3

Findings of this pilot study support the need for a multifaceted and longitudinal curriculum to indicated improved care among students particularly from urban centers (P = 0.0011),1 and ultimately, “that integrates transgender care throughout the four-year medical program,” Anna Napor told EndocrineWeb. This abstract received a presidential poster award.

NK3 Receptor Antagonist May Reverse Hyperandrogenism in PCOS 

Since most women with polycystic ovary syndrome (PCOS) experience both a high testosterone and a high ratio of luteinizing hormone to follicle-stimulating hormone, this first double-blind, placebo-controlled phase 2a proof of concept study, used a neurokinin-3 (NK3) antagonist, Fezoinetant (Ogeda, Belgium), to achieve a therapeutic benefit in targeting central neuroendocrine regulation as a safe and efficacious treatment for PCOS. 

With 64 women out of 105 completing the study, Graeme L. Fraser, PhD, chief scientific officer and director of drug discovery at Ogeda SA, told EndocrineWeb, “we saw a nice effect in reducing testosterone and a recalibration of the LH/FSH ratio to nearly 1, which is close to the normal range, effectively reducing hyperandrogenism, but there was no increase in frequency of the patients’ menses, which could be due to the limited timeframe of the study.”

Telemedicine Brings Better Diabetes Care to More Vets

Assessing the level of engagement among veterans without easy access to a VA facility, Archana Bandi, MD, clinical director of telehealth services at the VA Pittsburgh Healthcare System in Pennsylvania, reported on the outcomes of a study comparing telephone consultation partnering an endocrinologist with the patient’s primary care provider versus face-to-face sessions for glycemic control, blood pressure, and lipid levels over one year. 

“In reaching out to veterans who cannot travel or have a disability that makes it difficult for them to reach a VA facility, we found that delivering diabetes care by phone with an endocrine specialist in conjunction with the primary care provider close to home was comparable,” Dr. Bandi told EndocrineWeb, suggesting that when travel to an endocrinologist is not feasible, telemedicine offers a viable alternative.
Next Summary:
Overcoming Clinical Indifference to Obesity is a Public Health Imperative
Last updated on

close X